GoAI
Get started
Intelligent Bio Solutions Inc. logo

Intelligent Bio Solutions Inc.

INBS

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$2.51

−$0.14 · -5.28%

Aug 21, 4:00 PM ET

INBS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

31

Expensive

Momentum

17

Strong Down

Sentiment

52

Mixed

Risk resilience

12

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Harry Simeonidis
Listed since
Dec 23, 2020
Employees
54

Market position

Day range

Current $2.51

52-week range

Current $2.51

Open
$2.68
Previous close
$2.65
Volume
48.65K
0.45× average
Average volume
108.32K
Average daily volume
Market cap
1.62M USD
Beta
4.21
Market reference 1
50-day average
$2.1989
+14.15% above average
200-day average
$4.6671
-46.22% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.21M USD
P/E (TTM)
-0.27×
P/B (TTM)
0.67×
P/S (TTM)
0.38×
EV / EBITDA
-0.11×
Earnings yield
-366.99%
Free cash flow yield
-355.83%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
48.63%
Operating margin
-299.11%
Net margin
-294.91%
Return on equity
-225.57%
Return on assets
-104.10%
Return on invested capital
-176.09%

Financial health

Debt / equity
0.33×
Current ratio
1.44×
Altman Z-score
-11.51
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends154%-267%-687%-1107%Gross margin, FY2023: 25.99%Gross margin, FY2024: 45.81%Gross margin, FY2025: 40.85%Gross margin, FY2026: 48.63%Operating margin, FY2023: -1002.11%Operating margin, FY2024: -330.46%Operating margin, FY2025: -348.71%Operating margin, FY2026: -299.11%Net margin, FY2023: -845.89%Net margin, FY2024: -326.40%Net margin, FY2025: -346.23%Net margin, FY2026: -294.91%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2023 25.99%. Gross margin FY2024 45.81%. Gross margin FY2025 40.85%. Gross margin FY2026 48.63%. Operating margin FY2023 -1002.11%. Operating margin FY2024 -330.46%. Operating margin FY2025 -348.71%. Operating margin FY2026 -299.11%. Net margin FY2023 -845.89%. Net margin FY2024 -326.40%. Net margin FY2025 -346.23%. Net margin FY2026 -294.91%.

Income trends

Revenue

4.22M USD+38.09%

Operating income

−12.61M USD-18.45%

Net income

−12.43M USD-17.62%
Income trends across reported periods5.9M USD−831.8K USD−7.56M USD−14.29M USDRevenue, FY2023: 1.26M USDRevenue, FY2024: 3.11M USDRevenue, FY2025: 3.05M USDRevenue, FY2026: 4.22M USDOperating income, FY2022: −8.34M USDOperating income, FY2023: −12.6M USDOperating income, FY2024: −10.28M USDOperating income, FY2025: −10.64M USDOperating income, FY2026: −12.61M USDNet income, FY2022: −8.31M USDNet income, FY2023: −10.63M USDNet income, FY2024: −10.16M USDNet income, FY2025: −10.57M USDNet income, FY2026: −12.43M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2023 1.26M USD. Revenue FY2024 3.11M USD. Revenue FY2025 3.05M USD. Revenue FY2026 4.22M USD. Operating income FY2022 −8.34M USD. Operating income FY2023 −12.6M USD. Operating income FY2024 −10.28M USD. Operating income FY2025 −10.64M USD. Operating income FY2026 −12.61M USD. Net income FY2022 −8.31M USD. Net income FY2023 −10.63M USD. Net income FY2024 −10.16M USD. Net income FY2025 −10.57M USD. Net income FY2026 −12.43M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue4.22M USD3.05M USD3.11M USD1.26M USD—
Cost of goods sold2.17M USD1.81M USD1.69M USD930.2K USD—
Gross profit2.05M USD1.25M USD1.43M USD326.67K USD—
Research and development3.37M USD2.4M USD1.67M USD507.42K USD3.85M USD
Selling, general, and administrative10.5M USD8.88M USD9.26M USD8.03M USD4.92M USD
Operating expenses14.66M USD11.89M USD11.71M USD12.92M USD8.34M USD
Interest income110.33K USD101.52K USD84.82K USD9.68K USD14.43K USD
Interest expense10.74K USD60.89K USD167.14K USD223.53K USD7.54K USD
Depreciation and amortization1.16M USD970.12K USD974.36K USD966.73K USD—
Operating income−12.61M USD−10.64M USD−10.28M USD−12.6M USD−8.34M USD
Net income−12.43M USD−10.57M USD−10.16M USD−10.63M USD−8.31M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 9 misses, 0 met estimates
Average EPS surprise
-153.47%
11 comparable reports
Latest EPS result
-1.34
Estimate -1.58 · Beat by 15.19%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.91-0.56-3.04-5.51Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 14, 2025: actual -5, estimate -3.2, surprise -56.25%, Miss. Q2 2025, reported May 14, 2025: actual -4.4, estimate -2.8, surprise -57.14%, Miss. Q3 2025, reported Aug 15, 2025: actual -3.6, estimate -1.2, surprise -200.00%, Miss. Q4 2025, reported Nov 13, 2025: actual -3.5, estimate -1.5, surprise -133.33%, Miss. Q1 2026, reported Feb 12, 2026: actual -2.82, estimate 0.4, surprise -805.00%, Miss. Q2 2026, reported May 12, 2026: actual -1.8, estimate 1.4, surprise -228.57%, Miss. Q3 2026, reported Aug 19, 2026: actual -1.34, estimate -1.58, surprise +15.19%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -1.31, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.73M5.32M2.92M516.37KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MetQ4 '26Estimate
Q1 2025, reported Feb 14, 2025: actual 607.49K USD, estimate 2.3M USD, surprise -73.59%, Miss. Q2 2025, reported May 14, 2025: actual 728.87K USD, estimate 3.3M USD, surprise -77.91%, Miss. Q3 2025, reported Aug 15, 2025: actual 843.88K USD, estimate 4.3M USD, surprise -80.37%, Miss. Q4 2025, reported Nov 13, 2025: actual 1.11M USD, estimate 4.8M USD, surprise -76.84%, Miss. Q1 2026, reported Feb 12, 2026: actual 896.77K USD, estimate 5.5M USD, surprise -83.70%, Miss. Q2 2026, reported May 12, 2026: actual 1.06M USD, estimate 7.2M USD, surprise -85.27%, Miss. Q3 2026, reported Aug 19, 2026: actual 1.22M USD, estimate 1.22M USD, surprise 0.00%, Met estimate. Q4 2026, reported Nov 11, 2026: actual —, estimate 1.42M USD, surprise —, Comparison unavailable.

INBS news

globenewswire.com

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units

Read source
benzinga.com

Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit.

Read source
globenewswire.com

Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification

Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it pursues FDA clearance Recertification aligns with the FDA's newly amended…

Read source
globenewswire.com

Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today…

Read source
globenewswire.com

Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today…

Read source
globenewswire.com

Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today…

Read source

INBS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research INBS

research.disclaimer